InterMune To Release First Quarter Financial Results On April 24

       InterMune To Release First Quarter Financial Results On April 24

PR Newswire

BRISBANE, Calif., April 17, 2013

BRISBANE, Calif., April 17, 2013 /PRNewswire/ --InterMune, Inc. (NASDAQ:
ITMN) today announced that it will release its first quarter 2013 financial
results at the close of the U.S. markets on Wednesday, April 24, 2013. A live
conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern
time that same day.

(Logo: http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

Interested investors and others may participate in the conference call by
dialing 800-891-8257 (U.S.) or +1 212-271-4651 (international), conference
ID#21655193. A replay of the webcast and teleconference will be available on
the company's website approximately three hours after the call. To access the
live webcast, please log on to the company's website at www.intermune.com at
least 15 minutes prior to the start of the call to ensure adequate time for
any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call
and can be accessed by dialing 800-633-8284 (U.S.) or +1 402-977-9140
(international), and entering the conference ID#21655193.

About InterMune

InterMune is a biotechnology company focused on the research, development and
commercialization of innovative therapies in pulmonology and orphan fibrotic
diseases. In pulmonology, InterMune is focused on therapies for the treatment
of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.
Pirfenidone, the only medicine approved for IPF anywhere in the world, is
approved for marketing by InterMune in the EU and Canada as Esbriet^® and is
currently in a Phase 3 clinical trial to support regulatory registration in
the United States. InterMune's research programs are focused on the discovery
of targeted, small-molecule therapeutics and biomarkers to treat and monitor
serious pulmonary and fibrotic diseases.For additional information about
InterMune and its R&D pipeline, please visit www.intermune.com.

SOURCE InterMune, Inc.

Website: http://www.intermune.com
Contact: Jim Goff, InterMune, Inc., 415-466-2228, jgoff@intermune.com
 
Press spacebar to pause and continue. Press esc to stop.